The Short Bowel Syndrome market is divided into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa based on regional segmentation. During the anticipated period, North America is expected to dominate the Short Bowel Syndrome Market. The growth of the North American short bowel syndrome market is anticipated to be driven by the rising number of prescriptions for glucagon-like peptide treatment in the U.S.
Additionally, it is anticipated that North America will maintain its lead because glutamine and growth hormone are only approved for the treatment of SBS in the U.S. Consumers' growing awareness of short bowel syndrome and excellent reimbursement plans are expected to drive the regional market during the forecast period.
Read More:
https://knackersblogger.blogspot.com/2022/12/the-global-short-bowel-syndrome-market.html
